Showing 1 - 9 results of 9 for search '"Endometrial cancer"', query time: 0.02s Refine Results
  1. 1
    Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

    Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors by Martina S.J. McDermott (15206951)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 2
    Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

    Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors by Martina S.J. McDermott (15206951)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

    Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors by Martina S.J. McDermott (15206951)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

    Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors by Martina S.J. McDermott (15206951)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

    Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors by Martina S.J. McDermott (15206951)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

    Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors by Martina S.J. McDermott (15206951)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

    Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors by Martina S.J. McDermott (15206951)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

    Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors by Martina S.J. McDermott (15206951)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

    Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors by Martina S.J. McDermott (15206951)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: